Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 66Neutropenia 16Triple Negative Breast Neoplasms 8Breast Neoplasms, Male 6Inflammatory Breast Neoplasms 4Ovarian Neoplasms 3Lung Neoplasms 3Neoplasms 2Febrile Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Pain 1Melanoma 1Lymphoma, Non-Hodgkin 1Locally Advanced Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Early Stage Breast Cancer 1Fever 1Early Stage Breast Cancer 1Colorectal Neoplasms 1Chemotherapy-Induced Febrile Neutropenia 1Carcinoma, Renal Cell 1Carcinoma 1Breast Diseases 1Breast Cancer Metastatic 1Breast Cancer Female 1Adenocarcinoma 1

Interventions

pertuzumab 2Paclitaxel 2Neoadjuvant Therapy 2Docetaxel 2Carboplatin 2pyrotinib 1pegfilgrastim 1Trastuzumab 1Mastectomy, Modified Radical 1Letrozole 1Hydralazine 1Doxorubicin 1Cyclophosphamide 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Breast Cancer × pegfilgrastim × Breast × Clear all
NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
7 enrolled 10 charts
Breast

Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡